
GSK and Sanofi to supply US government with 100 million doses of COVID-19 vaccine
Sanofi and GSK have announced a collaborative effort with the US government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza… Read More















